Hydroxystenozole
From Wikipedia, the free encyclopedia
![]() |
|
Identifiers | |
---|---|
|
|
Synonyms | NSC-43194; 17α-Methyl-2'H-androsta-2,4-dieno[3,2-c]pyrazol-17β-ol; 17β-Hydroxy-17α-methylandrost-4-eno[3,2-c]-pyrazole |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C21H30N2O |
Molar mass | 326.48 g/mol |
3D model (Jmol) | |
|
|
|
|
![]() ![]() |
Hydroxystenozole (INN), also known as 17α-methylandrost-4-eno[3,2-c]pyrazol-17β-ol, is an orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of testosterone that was described in the literature in 1967 but was never marketed.[1] It is closely related to stanozolol (17α-methyl-5α-androstano[3,2-c]pyrazol-17β-ol), differing from it only in hydrogenation (i.e., double bonds and their placement).
References[edit]
- ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 668. ISBN 978-1-4757-2085-3.
![]() |
This article about a steroid is a stub. You can help Wikipedia by expanding it. |
![]() |
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |